Evaluating vaccinia virus cytokine co-expression in TLR GKO mice

Immunology and Cell Biology

Volumn 89, Issue 6, 2011, Pages 706-715

  Sutherland, Duncan B ^a   Ranasinghe, Charani ^a   Regner, Matthias ^a   Phipps, Simon ^b   Matthaei, Klaus I ^a,c   Day, Stephanie L ^a,d   Ramshaw, Ian A ^a  

^a Biology and Environment   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d BURNET INSTITUTE   (Australia)

Author keywords

cytokines; MyD88 ; pox viruses; Toll like receptors

Indexed keywords

BETA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; ECTROMELIA VIRUS; FEMALE; GENE; HOST RESISTANCE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; VACCINIA VIRUS; VIRUS INFECTION; VIRUS REPLICATION; WILD TYPE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CERCOPITHECUS AETHIOPS; CYTOKINES; ECTROMELIA VIRUS; ECTROMELIA, INFECTIOUS; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENETIC VECTORS; HUMANS; INTERFERON-BETA; INTERLEUKIN-12; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; PHENOTYPE; TOLL-LIKE RECEPTORS; VACCINIA VIRUS; VIRUS REPLICATION;

ECTROMELIA VIRUS; MUS; POXVIRIDAE; VACCINIA VIRUS;

EID: 80051701532     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.157     Document Type: Article

References (67)

1. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006; 7: 131-137. (Pubitemid 43135878)
2. Bowie AG, Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol 2008; 8: 911-922.
3. Muruve DA, Petrilli V, Zaiss AK, White LR, Clark SA, Ross PJ et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008; 452: 103-107. (Pubitemid 351355095)
4. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev 2009; 227: 75-86.
5. Zhou S, Kurt-Jones EA, Mandell L, Cerny A, Chan M, Golenbock DT et al. MyD88 is critical for the development of innate and adaptive immunity during acute lymphocytic choriomeningitis virus infection. Eur J Immunol 2005; 35: 822-830. (Pubitemid 40425538)
6. Mansur DS, Kroon EG, Nogueira ML, Arantes RM, Rodrigues SC, Akira S et al. Lethal encephalitis in myeloid differentiation factor 88-deficient mice infected with herpes simplex virus 1. Am J Pathol 2005; 166: 1419-1426. (Pubitemid 40586512)
7. Samuelsson C, Hausmann J, Lauterbach H, Schmidt M, Akira S, Wagner H et al. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest 2008; 118: 1776-1784. (Pubitemid 351632380)
8. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1: 398-401.
9. Lang KS, Navarini AA, Recher M, Lang PA, Heikenwalder M, Stecher B et al. MyD88 protects from lethal encephalitis during infection with vesicular stomatitis virus. Eur J Immunol 2007; 37: 2434-2440. (Pubitemid 47423614)
10. Town T, Bai F, Wang T, Kaplan AT, Qian F, Montgomery RR et al. To ll-l ike r ecepto r 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing. Immunity 2009; 30: 242-253.
11. Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K et al. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 2002; 169: 6668-6672. (Pubitemid 36899248)
12. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M et al. Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity 1998; 9: 143-150. (Pubitemid 28361303)
13. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998; 2: 253-258. (Pubitemid 128373651)
14. Uematsu S, Akira S. Toll-like receptors and Type I interferons. J Biol Chem 2007; 282: 15319-15323.
15. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-376. (Pubitemid 37174535)
16. Szebeni B, Veres G, Dezsofi A, Rusai K, Vannay A, Mraz M et al. Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease. Clin Exp Immunol 2008; 151: 34-41. (Pubitemid 350230984)
17. Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, Gros P et al. Endotoxin-tolerant mice have mutations in toll-like receptor 4 (Tlr4). J Exp Med 1999; 189: 615-625. (Pubitemid 29193362)
18. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863-869. (Pubitemid 32983021)
19. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM et al. Functional role of type I and type II interferons in antiviral defense. Science 1994; 264: 1918-1921. (Pubitemid 24245635)
20. Day SL, Ramshaw IA, Ramsay AJ, Ranasinghe C. Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy. J Immunol 2008; 180: 7158-7166.
21. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R et al. To l l-l i k e receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001; 31: 3026-3037. (Pubitemid 32994554)
22. Gherardi MM, Ramirez JC, Esteban M. IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J Gen Virol 2003; 84: 1961-1972. (Pubitemid 36927225)
23. Hou B, Reizis B, Defranco AL. Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and-extrinsic mechanisms. Immunity 2008; 29: 272-282.
24. Granucci F, Feau S, Angeli V, Trottein F, Ricciardi-Castagnoli P. Early IL-2 production by mouse dendritic cells is the result of microbial-induced priming. J Immunol 2003; 170: 5075-5081. (Pubitemid 36554737)
25. Karupiah G, Coupar BE, Andrew ME, Boyle DB, Phillips SM, Mullbacher A et al. Elevated natural killer cell responses in mice infected with recombinant vaccinia virus encoding murine IL-2. J Immunol 1990; 144: 290-298. (Pubitemid 20030491)
26. Gherardi MM, Ramirez JC, Rodriguez D, Rodriguez JR, Sano G, Zavala F et al. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. J Immunol 1999; 162: 6724-6733. (Pubitemid 29309398)
27. Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 2007; 4: e353.
28. Mukherjee S, Upham JW, Ramshaw I, Bundell C, van Bruggen I, Robinson BW et al. Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine IL-12. Cancer Gene Ther 2003; 10: 591-602. (Pubitemid 36988534)
29. Mukherjee S, Haenel T, Himbeck R, Scott B, Ramshaw I, Lake RA et al. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther 2000; 7: 663-670. (Pubitemid 30314050)
30. Harte MT, Haga IR, Maloney G, Gray P, Reading PC, Bartlett NW et al. The poxvirus protein A52R targets toll-like receptor signaling complexes to suppress host defense. J Exp Med 2003; 197: 343-351. (Pubitemid 36184241)
31. Stack J, Haga IR, Schroder M, Bartlett NW, Maloney G, Reading PC et al. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J Exp Med 2005; 201: 1007-1018. (Pubitemid 40524469)
32. Zhu J, Martinez J, Huang X, Yang Y. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 2007; 109: 619-625. (Pubitemid 46105962)
33. Hutchens M, Luker KE, Sottile P, Sonstein J, Lukacs NW, Nunez G et al. TLR3 increases disease morbidity and mortality from vaccinia infection. J Immunol 2008; 180: 483-491.
34. Quigley M, Martinez J, Huang X, Yang Y. A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection. Blood 2009; 113: 2256-2264.
35. Zhao Y, De Trez C, Flynn R, Ware CF, Croft M, Salek-Ardakani S. The adaptor molecule MyD88 directly promotes CD8Tcell responses to vaccinia virus. J Immunol 2009; 182: 6278-6286.
36. Barbalat R, Lau L, Locksley RM, Barton GM. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat Immunol 2009; 10: 1200-1207.
37. Liu TC, Kirn D. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther 2008; 15: 877-884. (Pubitemid 351791475)
38. Fenner F. Classic paper: Fenner on the exanthemata. Rev Med Virol 2006; 16: 353-363.
39. Ramshaw IA, Ramsay AJ, Karupiah G, Rolph MS, Mahalingam S, Ruby JC. Cytokines and immunity to viral infections. Immunol Rev 1997; 159: 119-135. (Pubitemid 27499864)
40. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity 2006; 25: 373-381. (Pubitemid 44354218)
41. Ranasinghe C, Medveczky JC, Woltring D, Gao K, Thomson S, Coupar BE et al. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1. Vaccine 2006; 24: 5881-5895. (Pubitemid 44173003)
42. Ranasinghe C, Turner SJ, McArthur C, Sutherland DB, Kim JH, Doherty PC et al. Mucosal HIV-1 pox virus prime-boost immunization induces high-avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles. J Immunol 2007; 178: 2370-2379. (Pubitemid 46233436)
43. Tscharke DC, Karupiah G, Zhou J, Palmore T, Irvine KR, Haeryfar SM et al. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 2005; 201: 95-104. (Pubitemid 40130087)
44. Karupiah G, Coupar B, Ramshaw I, Boyle D, Blanden R, Andrew M. Vaccinia virus-mediated damage of murine ovaries and protection by virus-expressed interleukin-2. Immunol Cell Biol 1990; 68: 325-333.
45. Karupiah G, Blanden RV. Anti-asialo-GM1 inhibits vaccinia virus infection of murine ovaries: asialo-GM1 as an additional virus receptor? Immunol Cell Biol 1990; 68: 343-346.
46. Martinez J, Huang X, Yang Y. Direct action of type I IFN on NK cells is required for their activation in response to vaccinia viral infection in vivo. J Immunol 2008; 180: 1592-1597.
47. Chan SH, Perussia B, Gupta JW, Kobayashi M, Pospisil M, Young HA et al. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 1991; 173: 869-879.
48. Patera AC, Pesnicak L, Bertin J, Cohen JI. Interleukin 17 modulates the immune response to vaccinia virus infection. Virology 2002; 299: 56-63. (Pubitemid 35007511)
49. Jackson RJ, Ramsay AJ, Christensen CD, Beaton S, Hall DF, Ramshaw IA. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 2001; 75: 1205-1210. (Pubitemid 32094679)
50. Hogan SP, Foster PS, Tan X, Ramsay AJ. Mucosal IL-12 gene delivery inhibits allergic airways disease and restores local antiviral immunity. Eur J Immunol 1998; 28: 413-423. (Pubitemid 28101715)
51. Wang Y, Chaudhri G, Jackson RJ, Karupiah G. IL-12p40 and IL-18 play pivotal roles in orchestrating the cell-mediated immune response to a poxvirus infection. J Immunol 2009; 183: 3324-3331.
52. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 2005; 202: 637-650. (Pubitemid 41248415)
53. Badovinac VP, Porter BB, Harty JT. Programmed contraction of CD8(+) T cells after infection. Nat Immunol 2002; 3: 619-626. (Pubitemid 34752470)
54. Le Bon A, Etchar N, Rossmann C, Ashton M, Hou S, Gewert D et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003; 4: 1009-1015. (Pubitemid 37265922)
55. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009; 458: 514-518.
56. Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nature 2010; 11: 395-402.
57. Roberts TL, Idris A, Dunn JA, Kelly GM, Burnton CM, Hodgson S et al. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 2009; 323: 1057-1060.
58. Long EO. Ready for prime time: NK cell priming by dendritic cells. Immunity 2007; 26: 385-387. (Pubitemid 46603004)
59. Lauwerys BR, Renauld JC, Houssiau FA. Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine 1999; 11: 822-830. (Pubitemid 29537530)
60. Matikainen S, Paananen A, Miettinen M, Kurimoto M, Timonen T, Julkunen I et al. IFN-alpha and IL-18 synergistically enhance IFN-gamma production in human NK cells: differential regulation of Stat4 activation and IFN-gamma gene expression by IFN-alpha and IL-12. Eur J Immunol 2001; 31: 2236-2245. (Pubitemid 32640741)
61. Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH. Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 2007; 7: 1705-1721. (Pubitemid 350157496)
62. Kim GG, Donnenberg VS, Donnenberg AD, Gooding W, Whiteside TL. A novel multi-parametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay. J Immunol Methods 2007; 325: 51-66. (Pubitemid 47238289)
63. You TG, Wang HS, Yang JH, Qian QJ, Fan RF, Wu MC. Transfection of IL-2 and/or IL-12 genes into spleen in treatment of rat liver cancer. World J Gastroenterol 2004; 10: 2190-2194.
64. Gollob JA, Schnipper CP, Murphy EA, Ritz J, Frank DA. The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation. J Immunol 1999; 162: 4472-4481. (Pubitemid 29314844)
65. Boyle DB, Coupar BE, Both GW. Multiple-cloning-site plasmids for the rapid construction of recombinant poxviruses. Gene 1985; 35: 169-177. (Pubitemid 15067259)
66. Asselin-Paturel C, Boonstra A, Dalod M, Durand I, Yessaad N, Dezutter-Dambuyant C et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2001; 2: 1144-1150. (Pubitemid 33130149)
67. Mullbacher A, Hill AB, Blanden RV, Cowden WB, King NJ, Hla RT. Alloreactive cytotoxic T cells recognize MHC class I antigen without peptide specificity. J Immunol 1991; 147: 1765-1772.